Skip to main content

Clinical Trials for Transitional Cell Cancer of the Renal Pelvis and Ureter

Trials 1-25 of 32

Testing the Role of DNA Released from Tumor Cells into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study
Status: Active
Location: 461 locations
Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) after Surgery to Remove all Known Sites of Kidney Cancer
Status: Active
Location: 421 locations
Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy before Surgery for Patients with High-Grade Upper Urinary Tract Cancer
Status: Active
Location: 207 locations
A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2
Status: Active
Location: 15 locations
Study of Zanzalintinib in Combination With Immuno-Oncology Agents in Participants With Solid Tumors
Status: Active
Location: 17 locations
Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial Carcinoma
Status: Active
Location: 21 locations
Neoadjuvant Enfortumab Vedotin for the Treatment of Patients with High-Grade Urothelial Cancer of the Upper Urinary Tract
Status: Active
Location: 8 locations
A Substudy of Investigational Agents in Programmed Cell Death-1/Ligand 1 (PD-1/L1) Refractory Locally Advanced or Metastatic Urothelial Carcinoma (mUC) (MK-3475-04A)
Status: Active
Location: 9 locations
A Phase 3 Single-arm Study of UGN-104 for the Treatment of Low-grade Upper Tract Urothelial Cancer
Status: Active
Location: 6 locations
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
Status: Active
Location: 7 locations
Sacituzumab Govitecan, Enfortumab Vedotin and Pembrolizumab for the Treatment of Locally Advanced or Metastatic Urothelial Cancer
Status: Active
Location: 6 locations
A Phase 1 Study of BHV-1530 in Advanced Solid Tumors
Status: Active
Location: 7 locations
Locally Ablative Therapy for the Treatment of Oligo-progressive Prostate Cancer, Urinary Tract Cancer or Kidney Cancer, LAYOVER Trial
Status: Active
Location: 4 locations
A Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors (IDeate-PanTumor02)
Status: Active
Location: 4 locations
Phase 2A/B Efficacy and Safety of Dabogratinib in Participants With Low Grade Upper Tract Urothelial Carcinoma
Status: Active
Location: 3 locations
Enfortumab Vedotin and Pembrolizumab for the Treatment of Patients with High Grade Upper Tract Urothelial Cancer who are not Candidates for, or Refuse, Nephroureterectomy
Status: Active
Location: 2 locations
Neoadjuvant Enfortumab Vedotin and Pembrolizumab for the Treatment of Patients with Upper Tract Urothelial Cancer, NEPTUNE Trial
Status: Active
Location: 2 locations
A Study to Evaluate the Efficacy and Safety of Autogene Cevumeran With Nivolumab Versus Nivolumab Alone in Participants With High-risk Muscle-invasive Urothelial Carcinoma (MIUC)
Status: Active
Location: 2 locations
Nephroureterectomy with and without Lymph Node Dissection for the Treatment of Upper Tract Urothelial Cancer
Status: Active
Location: 2 locations
Hypotonic Fluids versus Chemotherapy Wash for the Prevention of Bladder Cancer in Patients with Upper Tract Urothelial Cancer
Status: Active
Location: UT Southwestern/Simmons Cancer Center-Dallas, Dallas, Texas
Pembrolizumab and Enfortumab Vedotin with Pembrolizumab Prior to and After Radical Nephroureterectomy for High-Risk Upper Tract Urothelial Cancer
Status: Active
Location: UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California
Therapeutic Plasma Exchange with Enfortumab Vedotin and Pembrolizumab for the Treatment of Metastatic Refractory Bladder and Urinary Tract Cancers, RECIPE-B1 Trial
Status: Active
Location: Mayo Clinic in Rochester, Rochester, Minnesota
Adjuvant Sacituzumab Govitecan and Nivolumab for the Treatment of Patients with Muscle-Invasive Urothelial Carcinoma at High-Risk for Recurrence
Status: Active
Location: UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange, California
Lurbinectedin With or Without Avelumab in Small Cell Carcinoma of the Bladder (LASER)
Status: Active
Location: National Institutes of Health Clinical Center, Bethesda, Maryland
Neoadjuvant Immunotherapy (Atezolizumab and Tiragolumab) for the Treatment of Cisplatin-Ineligible Resectable High-Risk, Muscle-Invasive Urothelial Cancer
Status: Active
Location: UT MD Anderson Cancer Center, Houston, Texas